Testing NPT 2042 for absence seizures in genetic epilepsy
Part of Brain & nervous system clinical trials.
This trial tests a new medication called NPT 2042 for people with a type of epilepsy that causes brief staring spells (absence seizures). It aims to see if the drug can reduce seizure frequency compared to a placebo (an inactive pill).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 75 years old.
- You have been diagnosed with genetic generalized epilepsy that causes absence seizures (brief staring spells).
- You have had at least 4 episodes of abnormal brain activity lasting 3 seconds or more on a 3-day EEG test.
- You are taking a stable dose of at least one seizure medicine for at least 30 days.
- You are in generally good health otherwise, with no severe intellectual disability, active liver disease, or recent drug/alcohol abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
This trial tests a new cell therapy (NRTX-1001) for people with epilepsy that starts in both sides of the brain's temporal lobes and doesn't get better with medication. It aims to reduce or stop seizures.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
This Phase 3 trial tests XEN1101 added to your current seizure medicines for people with primary generalized tonic-clonic seizures. It’s for seizures that have not fully stopped even after trying at least two appropriate medicines.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
Hear when a new Epilepsy, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.